 CAMBRIDGE, Mass., May 17, 2022 GLOBE NEWSWIRE -- Surface Oncology Nasdaq: SURF, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in two upcoming investor conferences: 